Table 1.
Antibiotic susceptibility of AB341-IK15. Susceptibility testing results for the CANWARD panel of antibiotics according to the Clinical Laboratory Standards Institute (CLSI) broth microdilution guidelines. AB341-IK15 is resistant to CAZ as indicated in bold and has an intermediate susceptibility to CRO and TZP as indicated in the underlined text. All values that indicate resistance are highlighted in bold text and those that indicate intermediate resistance are underlined. Data is displayed based on three biological replicates
|
Strain |
AMK |
CFZ |
FEP |
FOX |
CAZ |
BPR |
C/T |
CRO |
CIP |
CLR |
CLI |
CST |
DAP |
DOX |
ETP |
GEN |
IPM |
LZD |
MEM |
NIT |
TZP |
TOB |
SXT |
VAN |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
ATCC17978 |
1 |
>128 |
4 |
>32 |
8 |
0.5 |
2 |
16 |
0.25 |
32 |
>8 |
2 |
>16 |
0.25 |
4 |
1 |
0.25 |
>16 |
0.5 |
>512 |
4 |
1 |
4 |
>32 |
|
AB030 |
64 |
>128 |
>64 |
>32 |
>32 |
>32 |
32 |
>64 |
>16 |
>32 |
>8 |
0.5 |
>16 |
32 |
>32 |
>32 |
>32 |
>16 |
>32 |
>512 |
>512 |
64 |
>8 |
>32 |
|
AB341-IK15 |
2 |
>128 |
4 |
>32 |
32 |
0.5 |
4 |
16 |
0.25 |
32 |
>8 |
1 |
>16 |
1 |
4 |
≤0.5 |
0.5 |
>16 |
0.5 |
512 |
32 |
≤0.5 |
≤0.12 |
>32 |
AMK, Amikacin; BPR, Ceftobiprole; CAZ, Ceftazidime; CFZ, Cefazolin; CIP, Ciprofloxacin; CLI, Clindamycin; CLR, Clarithromycin; CRO, Ceftriaxone; CST, Colistin; C/T, Ceftolazane/tazobactam; DAP, Daptomycin; DOX, Doxycycline; ETP, Ertapenem; FEP, Cefepime; FOX, Cefoxitin; GEN, Gentamicin; IPM, Imipenem; LZD, Linezolid; MEM, Meropenem; NIT, Nitrofurantoin; SXT, Trimethoprim/Sulphamethoxazole; TOB, Tobramycin; TZP, Piperacillin/Tazobactam; VAN, Vancomycin.